

SHORT CURRICULUM VITAE

Sven Ove Ögren

Prof., Dept. of Neuroscience, Karolinska Institutet
S-171 77 Stockholm, SWEDEN, Phone: + 46-8-52487074
Fax: + 46-8-302875
E-mail: Sven.Ove.Ogren@ki.se

Professional (academic) preparation

Medical Doctor of Science (Ph.D.) at the Department of Neurobiology and Histology, Karolinska Institutet (1985) Thesis: "Evidence for a role of brain serotonergic neurotransmission in avoidance learning", Acta Physiologica Scandinavica 125 (suppl. 544) pp. 1-71 (1985).

Associate Professor (Docent) of Neurobiology(1986), Department of Histology, Karolinska Institutet, Stockholm.

Professor (Adjunct Professor) of Neurobiology(1987), Department of Neuroscience, Karolinska Institutet.

Head of the Division of Behavioral Neuroscience(1998), Department of Neuroscience, Karolinska Institutet.

Professional (industrial) experience

Preclinical Projectleader for (CNS) research projects at Astra Läkemedel(1974).

Vice President of Preclinical Research, Senior Scientific Adviser and Senior Director at Astra Alab AB (now Astra Zeneca)(1989).

Preclinical projectleader of the development of zimelidine (1972-1982), the first serotonin reuptake inhibitor (SSRI) launched in the world (1982).

Inventor and Project leader of novel types of antipsychotic drugs(1978-1986), resulting in the selective dopamine D₂ receptor antagonist remoxipride (launched in 1992).

Inventor and project leader of the development of the selective dopamine D-2 receptor antagonists, the resorcylamides raclopride, FLB 463 and FLB 457. These compounds, in particular raclopride, are used as PET ligands all over the world..

Project leadership of six preclinical research projects at Astra Läkemedel AB (now AstraZeneca), Södertälje. Five of these projects resulted in the development of compounds that were examined in clinical trials e.g. the two selective 5-HT uptake inhibitors, zimelidine and alaproclate, the monoamine oxidase A-selective inhibitor amiflamine, and two selective dopamine D₂ receptor antagonists, remoxipride and raclopride.

Patents

30 international patents granted for new chemical entities and new treatment possibilities in depression and schizophrenia that were received jointly with different co-workers. These patents cover compounds that have been launched in the market (remoxipride) or tested clinically (raclopride, alaproclate)

Post-doc and senior scientist supervision (1995-present)

Katerina Antoniou, 1995-1996;Henrik Bengtsson, 2003- 2004;David Blacker, 1994;ClaudioD'Addario, 2006-2007;Charlotta Eriksson, 2005; Raphaël Faucard, 2007-2009;Lydia Giménez-Llort, 1996-1998;Björn Johansson, 2002-2007;Ulrika Kahl, 1999;Alexander Kuzmin, 2000-2004;Nather Madjid, 2001-2006, 2009-; Joana Marques, 2006;Kamlesh K. Meos, 1994-1995;Ilga Misane, 1993-1996;Peter Osborne, 1999;Ilkka

Reenilä, 2001-2002; John Robinson, 2008; Patricia Rojas-Castañeda, 2002-2003; Oliver Stiedl, 2005; Fadao Tai, 2006-2007; John Talpos, 2003; Erika Toth, 2007-2008; Valentina Vengeline, 2005

Supervision of PH.D. students (year of dissertation)

Main supervisor: P. Schött (2000), "Hippocampal galanin and acetylcholine in spatial learning"; J. Sandin (2000), "The hippocampal opioid system: Role in spatial learning"; H. Razani (2001), "Galanin. A modulator of serotonin transmission. Relevance for depression"; M. Luttgen (2004), "Serotonergic receptor subtypes in learning and memory"; E. Elvander-Tottie (2006) "Neurochemical regulators of the septohippocampal pathway: role in spatial and aversive learning"; E. Kuteeva (2007) "Brain galanin systems and their role in depression-like behaviour"; S. Beraki (2008) "Influenza A virus infection and NMDA receptor function: A behavioral and molecular study of relevance for schizophrenia"; T. Wardi (2010) "Galanin receptor subtypes in rodent models of mood disorders"; Co-supervisor: R. Diaz (1997), M. Bäckberg (2004), A. Mattsson (2005), Linnea Asp (2009), R. Andersson (2012).

Commission of trust

Counselor of the Executive Board of ECNP 2002-2005 and since 2010 Secretary of the Executive Board of ECNP.

Chairman of the Scientific Program Committee (SPC) of European College of Neuropsychopharmacology (ECNP) 2006-2009; Chairman of the Award Committee 2005-2008. Fellow American College of Neuropsychopharmacology (ACNP).

Invited chairman at 42 International Congresses.

Invited lecturer at 85 International congresses .

Prizes and Awards

Swedish American Foundation, one year scholarship at Towson State College, Baltimore, 1964.

The Hilda and Alfred Erikssons Prize, Swedish Academy of Sciences, 1995.

Oswald Schmiedeberg's medal, Department of Pharmacology, University of Riga, Latvia, 1998.

Gold medal, University of Medical Informatics and Technology, Tyrol, Innsbruck, Austria, 2004.

Honorary member of the Austrian Society for Neuropsychopharmacology and Biological Psychiatry, Vienna, Austria, 2004.

Publications

Author of 370 original papers and book chapters as well as 35 review articles. More than 200 posters and 300 abstracts have been presented at international meetings.